06/04/09

Worms clue to poor performance of cholera vaccine

Hookworm, and other worm infections, can reduce the effectiveness of cholera vaccines Copyright: WHO

By: T.V. Padma

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Worms clue to poor performance of cholera vaccine</h1>
<h4>By: T.V. Padma</h4>
</div>
<br />
<br />

<div id="article-body">
<p>[NEW DELHI] A long-standing mystery about cholera vaccines — why they show promise in trials in the United States and Europe but perform disappointingly in endemic areas — may have been solved.</p>
<p>Researchers have shown that the vaccines are much less effective in people infected with intestinal worms.</p>
<p>People with worms produce fewer antibodies against the cholera bacterium <em>Vibrio cholerae </em>than those free of worms. De-worming programmes in areas where cholera is endemic could help counter this, they say.</p>
<p><span>The study tested the immune responses of cholera patients with and without worm infections. Tests were conducted on 361 patients in Dhaka, Bangladesh, of whom 53 had intestinal worm infections — mostly roundworms, hookworms and tapeworms. </span></p>
<p><span>The researchers — scientists at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Massachusetts General Hospital and Harvard Medical School in Boston, United States — tested immune responses to two components of a cholera vaccine. </span></p>
<p><span>One is based on part of a lethal toxin produced by <em>V. cholerae</em>. The other is a sugar-based molecule called</span> lipopolysaccharide that makes the bacterium infectious.</p>
<p><span>They found that patients with intestinal worms had the lowest immunity to the cholera toxin and developed few antibodies to it in the intestines. Worm infection did not affect the immune response to </span>lipopolysaccharide.</p>
<p><span>The researchers say the finding provides an additional reason for de-worming programmes in cholera endemic areas. </span></p>
<p><span>More than five million cases of cholera occur worldwide, leading to around 100,000 deaths — mostly in poor areas in developing countries. These countries also have a high incidence of parasitic worm infections in the digestive tract, such as hookworms and tapeworms. </span></p>
<p><span>Bangladesh, for example, records 200 cholera cases for every 100,000 people each year, while 80 per cent of children have intestinal worms. Hospital data from Kolkata, India, and Kathmandu, Nepal, show almost a third of children with diarrhoeal diseases also have worm infections.</span></p>
<p><span>Firdausi Qadri, an immunologist at ICDRR,B, told SciDev.Net that scientists at his institute are trying to identify new or novel substances that produce an immune response as well as studying factors that can improve the immune response to cholera vaccines in children in South Asia. They are also investigating the use of anti-parasitic drugs to improve the immune response to cholera vaccines.</span></p>
<p><span>The study was published last week (31 March) in <em>PLoS Neglected Tropical Diseases</em>.</span></p>
<p><span><a target="_blank" href="http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000403" rel="noopener noreferrer">Link to full paper in <span>PLoS Neglected Tropical Diseases</span></a></span></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/news/worms-clue-to-poor-performance-of-cholera-vaccine/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/news/worms-clue-to-poor-performance-of-cholera-vaccine/",null,true])
</script>
</div>

[NEW DELHI] A long-standing mystery about cholera vaccines — why they show promise in trials in the United States and Europe but perform disappointingly in endemic areas — may have been solved.

Researchers have shown that the vaccines are much less effective in people infected with intestinal worms.

People with worms produce fewer antibodies against the cholera bacterium Vibrio cholerae than those free of worms. De-worming programmes in areas where cholera is endemic could help counter this, they say.

The study tested the immune responses of cholera patients with and without worm infections. Tests were conducted on 361 patients in Dhaka, Bangladesh, of whom 53 had intestinal worm infections — mostly roundworms, hookworms and tapeworms.

The researchers — scientists at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Massachusetts General Hospital and Harvard Medical School in Boston, United States — tested immune responses to two components of a cholera vaccine.

One is based on part of a lethal toxin produced by V. cholerae. The other is a sugar-based molecule called lipopolysaccharide that makes the bacterium infectious.

They found that patients with intestinal worms had the lowest immunity to the cholera toxin and developed few antibodies to it in the intestines. Worm infection did not affect the immune response to lipopolysaccharide.

The researchers say the finding provides an additional reason for de-worming programmes in cholera endemic areas.

More than five million cases of cholera occur worldwide, leading to around 100,000 deaths — mostly in poor areas in developing countries. These countries also have a high incidence of parasitic worm infections in the digestive tract, such as hookworms and tapeworms.

Bangladesh, for example, records 200 cholera cases for every 100,000 people each year, while 80 per cent of children have intestinal worms. Hospital data from Kolkata, India, and Kathmandu, Nepal, show almost a third of children with diarrhoeal diseases also have worm infections.

Firdausi Qadri, an immunologist at ICDRR,B, told SciDev.Net that scientists at his institute are trying to identify new or novel substances that produce an immune response as well as studying factors that can improve the immune response to cholera vaccines in children in South Asia. They are also investigating the use of anti-parasitic drugs to improve the immune response to cholera vaccines.

The study was published last week (31 March) in PLoS Neglected Tropical Diseases.

Link to full paper in PLoS Neglected Tropical Diseases